Member Info for Basser1

Some big buys today and number of buys also far exceeding sells. But of course that doesn’t mean anything -it’s something we are just used to.

Krone - particularly liked 1 April 2022 - Mr Dilley met with a rep of a biopharmaceutical company (referred to PARTY G) in connection with ongoing discussions regarding opportunities for licensing and other strategic transactions. As part of the discussions Dr Dilley and the rep discussed on a preliminary basis the possibility of a business combination between Sierra Oncology and Party G but deferred discussion to a future date. Sounds very much like a reference to SRA 737 to me.

https://quantisnow.com/i/2805369?utm_source=stocktwits

For those who like to rummage.

Thanks Krone. My view (although it does seems quite clear in the GSK press release) is that the takeover was deliberately portrayed as being focused on Momelotinib. The lack of any
detail about SRA 737 and the phase 1/2 trial results is frankly appalling as far as I am concerned. As a consequence, Sierra shareholders in my view have experienced the equivalent of daylight robbery. No wonder the lawyers are crawling over the fiduciary duties of the Sierra Board.
If the deal is secured, I would expect that one of GSKs main priorities will be to get the SRA 737 Anogenital cancer trial into stage 3 given the upbeat results of the phase1/2 trial. There is an unmet need here for further treatments so it would likely be given a fast track status. It would be good to know whether CRUKs contracting arm is currently proactive in initial discussions with GSK re the future of the SRA 737 licence. - but don’t hold your breath.

No. But I do think an early offer from a pharma may happen any time from now. It would make sense. Why wait on assets that have potential multiple indications. Once in trials it would be very expensive indeed.

Thanks MattyBoy.

Can’t seem to copy the BBC article. It’s called ‘ Hugh DNA analysis uncovers new Cancer clues” . It’s on the top right hand side of the health section. Grateful if someone could try and put it on here.

I give up. It’s an article on the BBC health section.

https://www.bbc.co.uk/news/uk-61041618. Apologies. Hope this is OK

https://www.bbc.co.uk/news/health-611775

Just on the BBC News this morning. SDC 1802 massive.

Thoth
This article may be of interest

https://mdpi-res.com/d_attachment/pharmaceutics/pharmaceutics-13-01446/article_deploy/pharmaceutics-13-01446.pdf?version=1631286048

The key point here is that the TO price will have to take account of the multiple indications that the Sareum pipeline covers. Increasing scientific evidence points to our own immune system as the root cause of most of our ailments. So
SAR737. Potential to treat up to 20 Solid Tumour Cancers
SDC1801 Potential to treat over 30 autoimmune conditions (with additional recent references to Parkinsons, Alzheimer’s and alopecia.
This is what the TO price has to recognise.

Sheck - If You used market cap . Ie price of stock multiplied by total number of shares the comparison is about the same isn’t it? All I was saying is the market cap should be much higher!

As far as I can remember, The Sareum share price was in the 7p range for a considerable period of time last year, bolstered by the anticipation of a Covid 19 trial. Today we are at an equivalent of 5.6p with a CTA imminent for SDC1801, GSK getting control of SRA737 enabling Cancer combo trials to proceed more quickly and the expectation of A Covid 19 trial sometime this year - likely in the Autumn. Looks like today, the penny dropped. This should be at least 8p Equivalent imho.GLA

Some chunky buys again today. Knowledgeable investors can see that SRA737 to GSK could be tailor made for early clinical trials on Small Cell Lung Cancer. It is an unmet need. How the share price has fallen in the last two days is beyond me. But that is Aim. I will be expecting some progress in the share price after the Easter break.

As a Sierra shareholder, I was very surprised this morning that an offer as low as 55 dollars had been accepted by the Sierra Board without seeking the view of its shareholders. The value of the Sierra pipeline including SRA 737 is in my opinion worth significantly more than 55 dollars!

Halter Dadeh LLP, an investigational law firm, is investigating Sierra for potential violation of the federal securities laws and/or breaches of Fiduciary duties relating to the Sierra sale to GSK for 55 dollars in cash.

The contract with Sierra for SRA737 is led by Institute of Cancer Research so any announcement would presumably come first from that body before any comment from Sareum.

Very comforting to know that Sareum Directors, John Reader and Tim Mitchell are tightly holding onto their shares. That certainly bodes well for the future.

Sierra 40 dollars pre market. Some mention of unusual call options. Way beyond me.